SEC Comment Letter 0000000000-23-001718 to Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI)
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Feb. 21, 2023 · CIK: 0001503802 · Accession: 0000000000-23-001718
AI Filing Summary & Sentiment
File numbers found in text: 333-269846
Letter
United States securities and exchange commission logo February 21, 2023 Michael Mano Senior Vice President and General Counsel Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 Re:Karyopharm Therapeutics Inc. Registration Statement on Form S-3 Filed February 17, 2023 File No. 333-269846 Dear Michael Mano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig Hilts
Show Raw Text
United States securities and exchange commission logo
February 21, 2023
Michael Mano
Senior Vice President and General Counsel
Karyopharm Therapeutics Inc.
85 Wells Avenue, 2nd Floor
Newton, MA 02459
Re:Karyopharm Therapeutics Inc.
Registration Statement on Form S-3
Filed February 17, 2023
File No. 333-269846
Dear Michael Mano:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Craig Hilts